Advertisement


Brian I. Rini, MD, on RCC: Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy

2021 ASCO Annual Meeting

Advertisement

Brian I. Rini, MD, of Vanderbilt University, discusses findings from KEYNOTE-426, the longest follow-up of a checkpoint inhibitor (pembrolizumab) combined with a VEGF/VEGFR inhibitor (axitinib) for first-line clear cell renal cell carcinoma. The trial results continue to support this combination as a standard of care for patients with previously untreated disease (Abstract 4500).



Related Videos

Breast Cancer

Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy

Priya Rastogi, MD, of the University of Pittsburgh, discusses results from the NRG Oncology/NSABP B-42 trial, which evaluated the utility of the 70-gene MammaPrint assay in predicting the benefit of extended letrozole therapy in patients who had completed 5 years of adjuvant endocrine therapy (Abstract 502).

Breast Cancer
Immunotherapy

Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen

Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab (Abstract 503).

Skin Cancer
Immunotherapy

Evan J. Lipson, MD, on Melanoma: Relatlimab and Nivolumab in First-Line Treatment of Advanced Disease

Evan J. Lipson, MD, of Johns Hopkins University, discusses primary phase III results from the RELATIVITY-047 study, which showed that relatlimab plus nivolumab as a fixed-dose combination may improve progression-free survival compared with nivolumab monotherapy in patients with advanced melanoma. This is the first study to demonstrate a benefit from dual inhibition of the LAG-3 and PD-1 pathways.

Leukemia
Lymphoma

Paolo Ghia, MD, PhD, on CLL/SLL and Ibrutinib Plus Venetoclax: A Primary Analysis of the CAPTIVATE Trial

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses phase II results from the CAPTIVATE study, which examined ibrutinib plus venetoclax as a fixed-duration first-line treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7501).

Gynecologic Cancers

Linda R. Mileshkin, MBBS, MD, on Cervical Cancer: Adjuvant Chemotherapy After Chemoradiation

Linda R. Mileshkin, MBBS, MD, of the Peter MacCallum Cancer Centre, discusses phase III findings from the OUTBACK trial, which showed that adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer did not improve either overall or progression-free survival (Abstract LBA3).

Advertisement

Advertisement




Advertisement